Amgen Inc. $AMGN Stock Sold by Milestone Asset Management LLC

Milestone Asset Management LLC cut its position in Amgen Inc. (NASDAQ:AMGN) by 82.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 3,059 shares of the medical research company’s stock after selling 14,819 shares during the quarter. Milestone Asset Management LLC’s holdings in Amgen were worth $1,290,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Ellsworth Advisors LLC lifted its stake in shares of Amgen by 1.9% in the third quarter. Ellsworth Advisors LLC now owns 22,754 shares of the medical research company’s stock worth $9,591,000 after acquiring an additional 425 shares in the last quarter. NFSG Corp boosted its holdings in Amgen by 14.0% in the third quarter. NFSG Corp now owns 816 shares of the medical research company’s stock valued at $339,000 after purchasing an additional 100 shares during the last quarter. Guyasuta Investment Advisors Inc. boosted its holdings in Amgen by 1.9% in the third quarter. Guyasuta Investment Advisors Inc. now owns 3,712 shares of the medical research company’s stock valued at $1,564,000 after purchasing an additional 70 shares during the last quarter. Murphy Middleton Hinkle & Parker Inc. grew its stake in Amgen by 1.4% during the 3rd quarter. Murphy Middleton Hinkle & Parker Inc. now owns 3,711 shares of the medical research company’s stock valued at $1,564,000 after purchasing an additional 50 shares in the last quarter. Finally, Walser Wealth Management Company A Ltd Liability Co grew its stake in Amgen by 7.9% during the 3rd quarter. Walser Wealth Management Company A Ltd Liability Co now owns 2,245 shares of the medical research company’s stock valued at $946,000 after purchasing an additional 165 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission after 24 weeks, potentially expanding the drug’s addressable market in a condition with limited treatment options. What Could Amgen 70% Remission Trial Result Mean For Its Pipeline?
• Positive Sentiment: UBS raised its price target for AMGN to $470, signaling greater confidence in the company’s outlook and supporting investor sentiment. UBS raises target for Amgen stock to USD 470.00
• Positive Sentiment: Investors are focusing on Amgen’s broader pipeline, including the MariTide obesity program, planned Phase 3 diabetes studies and recent regulatory momentum. These programs offer potential long-term growth beyond Amgen’s established products. Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
• Positive Sentiment: Erste Group Bank increased its FY2027 EPS forecast to $24.66 from $24.36, adding to evidence that some analysts see improving earnings potential.
• Positive Sentiment: A broader rotation away from technology stocks toward defensive and consumer-oriented companies may be helping support sentiment toward large pharmaceutical stocks.
• Neutral Sentiment: Amgen’s dividend yield is approximately 2.3%. Its dividend-growth prospects are being compared favorably with Merck’s because of Amgen’s reported cash-flow cushion, although the analysis does not represent a new dividend announcement. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
• Negative Sentiment: Risks remain: Bank of America Securities maintained a Sell rating, while recent insider activity showed seven sales and no purchases over six months. Some previously published analyst targets also remain well below the current trading range, highlighting valuation concerns. Bank of America Securities Remains a Sell on Amgen

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock worth $2,540,926 in the last 90 days. 0.85% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several analyst reports. Oppenheimer restated an “outperform” rating on shares of Amgen in a report on Wednesday, September 23rd. Argus upped their target price on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a research report on Wednesday, August 19th. TD Cowen increased their target price on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Wells Fargo & Company decreased their price target on shares of Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a research report on Monday. Finally, BMO Capital Markets decreased their price target on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $387.93.

Amgen Stock Performance

Shares of Amgen stock opened at $434.03 on Friday. The firm has a market cap of $234.65 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 3.12 and a beta of 0.41. The firm’s 50-day simple moving average is $415.11 and its 200-day simple moving average is $374.35. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s dividend payout ratio is presently 62.65%.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.